Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)


The number of allogeneic hematopoietic SCTs performed globally each year continues to increase, paralleled by an increased demand for donors of therapeutic cells. Donor characteristics and collection procedures have undergone major changes during recent decades, and further changes are foreseen. Information on short- and long-term donor outcomes is of crucial importance to ensure maximal donor safety and availability. Current data, predominantly from unrelated donors, give reliable information on the frequent early events associated with donation—most of them of mild-to-moderate intensity. Information on the type and relative risk of serious adverse reactions is more limited. Moreover, only few data exist on long-term donor outcome. On the basis of this need, recommendations for a minimum data set for prospective donor follow-up were developed in a workshop with the participation of an international group of investigators actively involved in allogeneic stem cell donation under the auspices of and approved by the Worldwide Network for Blood and Marrow Transplantation. Establishment of a standardized global follow-up for both, related and unrelated, donors will enable monitoring of the short- and long-term safety profiles of hematopoietic cell donation and form a solid basis for future donor selection and counseling.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Pasquini MC, Wang Z . Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides. 2010; Available at:

  2. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A et al. Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303: 1617–1624.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011; 46: 485–501.

    Article  CAS  PubMed  Google Scholar 

  4. Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC et al. Marrow harvesting from normal donors. Blood 1984; 64: 630–634.

    CAS  PubMed  Google Scholar 

  5. Anderlini P, Körbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903–908.

    CAS  PubMed  Google Scholar 

  6. Shaw BE, Ball L, Beksac M, Bengtsson M, Confer D, Diler S et al. Clinical Working Group; Ethics Working Group of the WMDA. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. Bone Marrow Transplant 2010; 45: 832–838.

    Article  CAS  PubMed  Google Scholar 

  7. van Walraven SM, Nicoloso-de Faveri G, Axdorph-Nygell UA, Douglas KW, Jones DA, Lee SJ et al. WMDA ethics and clinical working groups. Family donor care management: principles and recommendations. Bone Marrow Transplant 2010; 45: 1269–1273.

    Article  CAS  PubMed  Google Scholar 

  8. World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. Transplantation 2010; 90: 229–233.

    Google Scholar 

  9. Miller JP, Perry EH, Price TH, Bolan CD, Karanes C, Boyd TM et al. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 14 (9 Suppl): 29–36.

    Article  PubMed  Google Scholar 

  10. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604–3611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hölig K, Kramer M, Kroschinsky F, Bornhäuser M, Mengling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757–3763.

    Article  PubMed  Google Scholar 

  12. Favre G, Beksaç M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. European Group for Blood and Marrow Transplantation (EBMT). Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003; 32: 873–880.

    Article  CAS  PubMed  Google Scholar 

  13. Bredeson C, Leger C, Couban S, Simpson D, Huebsch L, Walker I et al. An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant 2004; 10: 405–414.

    Article  PubMed  Google Scholar 

  14. Tassi C, Tazzari PL, Bonifazi F, Giudice V, Nannetti A, Ricci F et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005; 36: 289–294.

    Article  CAS  PubMed  Google Scholar 

  15. de la Rubia J, de Arriba F, Arbona C, Pascual MJ, Zamora C, Insunza A et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008; 93: 735–740.

    Article  CAS  PubMed  Google Scholar 

  16. Horowitz MM, Confer DL . Evaluation of hematopoietic stem cell donors. Hematology Am Soc Hematol Educ Program 2005;, 469–475.

  17. Confer DL, Miller JP, Chell JW . Bone Marrow and peripheral blood cell donors an donor registries. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds). Thomas’ Hematopoietic Cell Transplantation. 4th edn. Blackwell Publishing, John Wiley & Sons Ltd, Chichester, West Sussex, UK, 2009, pp 544–558.

    Chapter  Google Scholar 

  18. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94–101.

    Article  PubMed  Google Scholar 

  19. Kodera Y, Yamamoto K, Kato S, Harada M, Kanda Y, Hamajima N et al. Safety and Risk of Allogeneic Peripheral Blood Stem Cell Donation: The Comprehensive Report of Nation-Wide Consecutively Pre-Registered 3,264 Family Donor Survey in 10years Project by Japan Society for Hematopoietic Cell Transplantation, ASH. 2010 Poster 1180.

  20. Niederwieser D, Gentilini C, Hegenbart U, Lange T, Moosmann P, Pönisch W et al. Transmission of donor illness by stem cell transplantation: should screening be different in older donors? Bone Marrow Transplant 2004; 34: 657–665.

    Article  CAS  PubMed  Google Scholar 

  21. Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A et al. Quality Assurance and Clinical Working Groups of the World Marrow Donor Association. Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. Bone Marrow Transplant 2008; 42: 9–14.

    Article  CAS  PubMed  Google Scholar 

  22. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642–650.

    Article  CAS  PubMed  Google Scholar 

  23. Goldman JM, Madrigal JA, Pamphilon D . Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006; 135: 651–652.

    Article  CAS  PubMed  Google Scholar 

  24. Confer DL, Miller JP . Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77–78.

    Article  PubMed  Google Scholar 

  25. Bacher U, Zander AR . Long-term safety of filgrastim (rhG-CSF) administration: application of haematopoietic growth factors in healthy individuals. Br J Haematol 2007; 137: 78–79.

    Article  PubMed  Google Scholar 

  26. Anderlini P, Champlin RE . Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008; 111: 1767–1772.

    Article  CAS  PubMed  Google Scholar 

  27. Tagliari C, Florêncio R, Ostronoff M . Fatal complication of peripheral blood stem cell (PBSC) donor after granulocyte-colony stimulating factor (G-CSF) stimulation. ISH. 2010; Poster 192.

  28. Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J . The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion 2008; 48: 1495–1501.

    Article  PubMed  Google Scholar 

  29. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31–34.

    Article  CAS  PubMed  Google Scholar 

  30. Hernández JM, Castilla C, Gutiérrez NC, Isidro IM, Delgado M, de las Rivas J et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005; 19: 1088–1091.

    Article  PubMed  Google Scholar 

  31. Hirsch B, Oseth L, Cain M, Trader E, Pulkrabek S, Lindgren B et al. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood 2011; 118: 2602–2608.

    Article  CAS  PubMed  Google Scholar 

  32. Schmidt AH, Mengling T, Pingel J, Rall G, Ehninger G . Follow up of 12559 unrelated donors of peripheral blood stem cells or bone marrow. ASH 2010.

  33. Hasenclever D, Sextro M . Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17 (Suppl 2): S28–S30.

    PubMed  Google Scholar 

  34. Jin P, Wang E, Ren J, Childs R, Shin JW, Khuu H et al. Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med 2008; 6: 39.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S et al. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 2008; 93: 347–355.

    Article  CAS  PubMed  Google Scholar 

  36. Donahue RE, Jin P, Bonifacino AC, Metzger ME, Ren J, Wang E et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood 2009; 114: 2530–2541.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Bortin MM, D'Amaro J, Bach FH, Rimm AA, van Rood JJ . HLA associations with leukemia. Blood 1987; 70: 227–232.

    CAS  PubMed  Google Scholar 

  38. Wang SS, Slager SL, Brennan P, Holly EA, De Sanjose S, Bernstein L et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 109: 3479–3488.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kroschinsky F, Hundertmark J, Mauersberger S, Hermes M, Poppe-Thiede K, Rutt C et al. Severe autoimmune hyperthyroidism after donation of growth factor-primed allogeneic peripheral blood progenitor cells. Haematologica 2004; 89: ECR05.

    PubMed  Google Scholar 

  40. Martino M, Console G, Dattola A, Callea I, Messina G, Moscato T et al. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Bone Marrow Transplant 2009; 44: 163–168.

    Article  CAS  PubMed  Google Scholar 

  41. Nicolini FE, Wattel E, Michallet AS, Bourgeot JP, Tremisi JP, Hequet O et al. Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion. Exp Hematol 2004; 32: 1033–1039.

    Article  PubMed  Google Scholar 

  42. Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment. Cancer 1981; 47: 207–214.

    Article  CAS  PubMed  Google Scholar 

  43. see adverse events.

  44. Leitner GC, Baumgartner K, Kalhs P, Biener D, Greinix HT, Hoecker P et al. Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study. Bone Marrow Transplant 2009; 43: 357–363.

    Article  CAS  PubMed  Google Scholar 

  45. Machaczka M, Kalaitzakis E, Eleborg L, Ljungman P, Hägglund H . Comparison of general vs regional anaesthesia for BM harvesting: a retrospective study of anaesthesia-related complications. Bone Marrow Transplant 2010; 45: 53–61.

    Article  CAS  PubMed  Google Scholar 

  46. Jeger A, Favre G, Lutz JM, Stern M, Usel M, Rovo A et al. Tumor incidence in related hematopoietic stem cell donors. Bone Marrow Transplant 2011; 46: 1240–1244.

    Article  CAS  PubMed  Google Scholar 

  47. Al-Ali HK, Bourgeois M, Krahl R, Edel E, Leiblein S, Poenisch W et al. The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2011; 46: 1296–1302.

    Article  CAS  PubMed  Google Scholar 

  48. Confer DL, Shaw BE, Pamphilon DH . WMDA guidelines for subsequent donations following initial BM or PBSCs. Bone Marrow Transplant 2011; 46: 1409–1412.

    Article  CAS  PubMed  Google Scholar 

  49. O’Donnell PV, Pedersen TL, Confer DL, Rizzo JD, Pulsipher MA, Stroncek D et al. Donor Health and Safety Working Committee from Center for International Blood and Marrow Transplant Research (CIBMTR). Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood 2010; 115: 5097–5101.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


This work was supported by the Swiss Blood Stem Cells (SBSC), generously supporting the organization of the meeting in Bern, and a grant from the Swiss National Research Foundation (406340-128111).

Author contributions: JPH, SMvW, NW, MB, HH, GNdF, AHS, MF, AG and DC attended the workshop and wrote the paper. BES, AM, JS, MDA, DW, MMH, HG, DW and YK contributed the comments and wrote the paper.

Participants of the donor outcome workshop in alphabetical order: F Audat (France Greffe de Moelle), L Ball (LUMC), M Bengtsson (Tobias Registry), L Brezinova (Czech Stem Cells Registry), E Buhrfeind (SBSC), D Confer (NMDP/CIBMTR), M Fechter (Europdonor), A Gratwohl (University Hospital Basel), H Hägglund (Karolinksa University Hospital, Huddinge/Nordic donor registry), J Halter (University Hospital Basel), R King (NMDP/CIBMTR), E Korthof (LUMC), E Lawlor (IBTS), E Marry (France Greffe de Moelle), T Mengling (DKMS), J Ng-McClelland (CW Bill Young DOD Marrow Donor Program), G Nicoloso de Faveri (SBSC), S Rajadhyasksha (Tata Memorial Hospital), A Rosenmayr (Austrian Bone Marrow Registry), M Reti (Szent Istvan and Szent Laszlo University hospital Budapest), AH Schmidt (DKMS), C Tassi (University Hospital Bologna), SM van Walraven (Europdonor, WMDA), N Worel (Medical University of Vienna), L Zahlavova (Czech Stem Cells Registry)

Author information

Authors and Affiliations


Corresponding author

Correspondence to J P Halter.

Ethics declarations

Competing interests

The authors declare that they have no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Halter, J., van Walraven, S., Worel, N. et al. Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transplant 48, 220–225 (2013).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


This article is cited by


Quick links